MedDataX Logo

Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

NCT03941587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-18

No results posted yet for this study

Summary

In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV). The primary objective is to compare the polyp closure rate at week 12 between the 2 treatment groups. The secondary aims include comparing visual, anatomical, treatment burden and clinical biomarkers between each treatment group.

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Aflibercept + reduced fluence photodynamic therapy (RF-PDT)

Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2

DRUG

Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)

Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy

Sponsors & Collaborators

  • National University Hospital, Singapore

    collaborator OTHER

  • Tan Tock Seng Hospital

    collaborator OTHER

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Gemmy Cheung Chui Ming · Singapore National Eye Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2024-06-06
Completion
2024-06-06

Countries

  • Singapore

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03941587 on ClinicalTrials.gov